Tag: clinical stage immuno-oncology company
June 10, 2018
5 Top Weekly NASDAQ Biotech Stocks: MEI Pharma on Top
MEI Pharma, Anavex Life Sciences, Trillium Therapeutics, Celldex Therapeutics and Ophthotech were last week's top gainers on the NASDAQ Biotechnology... April 29, 2018
5 Top Weekly NASDAQ Biotech Stocks: Eleven Biotherapeutics Up 45 Percent
Eleven Biotherapeutics, EyePoint Pharmaceuticals, Avid Bioservices, Cerecor and Celldex were last week's top gainers on the NASDAQ. April 26, 2018
Merus Announces Recent Corporate Developments and Financial Results for the Fourth Quarter and Full Year 2017
Merus (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced financial results for the fourth quarter... April 24, 2018
Immunovaccine and Incyte Expand Clinical Collaboration Evaluating Combination Immunotherapies in Advanced Recurrent Ovarian Cancer
Immunovaccine (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced that it has entered into an agreement with Incyte Corporation... April 19, 2018
Surface Oncology Announces $119.5 Million Aggregate Financing
Surface Oncology (Nasdaq:SURF), a clinical-stage immuno-oncology company developing next-generation antibody therapies that target the tumor microenvironment, today announced the pricing... April 16, 2018
New Preclinical Studies Reinforce the Potential for Heightened Anti-Cancer Activity of Combination Therapies Based on Immunovaccine’s Proprietary Delivery Platform
Immunovaccine (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced that it presented new research on its T-cell activating platform... April 10, 2018